2023
DOI: 10.3390/biomedicines11102721
|View full text |Cite
|
Sign up to set email alerts
|

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment

Annalisa Schirizzi,
Aram Arshadi,
Doron Tolomeo
et al.

Abstract: Metastatic gastric cancer (mGC) often has a poor prognosis and may benefit from a few targeted therapies. Ramucirumab-based anti-angiogenic therapy targeting the VEGFR2 represents a milestone in the second-line treatment of mGC. Several studies on different cancers are focusing on the major VEGFR2 ligand status, meaning VEGFA gene copy number and protein overexpression, as a prognostic marker and predictor of response to anti-angiogenic therapy. Following this insight, our study aims to examine the role of VEG… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…In China, a substantial portion of gastric cancer diagnoses occur at advanced stages, precluding the possibility of complete remission. Even among patients with early-stage disease who undergo surgical intervention, a notable proportion experience relapse and distant metastasis, therefore, it leads to a survival rate of less than 10 % in advanced gastric cancer patients within five years [ 2 ]. At present, individuals with advanced-stage gastric cancer primarily receive treatment regimens comprising chemotherapy and targeted therapies.…”
Section: Introductionmentioning
confidence: 99%
“…In China, a substantial portion of gastric cancer diagnoses occur at advanced stages, precluding the possibility of complete remission. Even among patients with early-stage disease who undergo surgical intervention, a notable proportion experience relapse and distant metastasis, therefore, it leads to a survival rate of less than 10 % in advanced gastric cancer patients within five years [ 2 ]. At present, individuals with advanced-stage gastric cancer primarily receive treatment regimens comprising chemotherapy and targeted therapies.…”
Section: Introductionmentioning
confidence: 99%